A Phase 1 interventional study of Cilofexor and Placebo in Nonalcoholic Steatohepatitis (NASH), sponsored by Gilead Sciences. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-12.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Gilead Sciences.
Among the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences, this one is the 12th largest by enrollment, is one of 6 that started in 2016, is one of 3 in phase 1, and was the 5th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 323 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →None of the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →
Of the 220 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 125 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is above the median of 60 across 1,177 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 161 across the 16 interventional studies. Of the 16 that completed or were terminated, 15 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and tolerability of escalating single- and multiple-oral doses of cilofexor, and characterize the single- and multiple-dose pharmacokinetics (PK) of cilofexor. The study will be conducted in 3 parts (Part A, Part B, and Part C). Participants will receive either cilofexor or cilofexor placebo.
Part A will proceed in 4 prespecified staggered cohorts. Within each cohort, the cumulative, blinded safety data will be evaluated for dose escalation from single-dose (Period 1) to multiple-dose (Period 2). Based on the available safety, pharmacokinetics, and/or pharmacodynamics (PD) data from cohorts in Part A and Part C (if applicable), total daily doses and frequency of dosing will be chosen for the cohorts in Part B. Parts B and C will consist of adaptive cohorts and may be initiated in parallel. Part B cohorts may be initiated in parallel with cohorts in Part A if the total dose under evaluation is at or below a dose already evaluated.
This study is partially blinded (no one is blinded on Day -1).
Key Inclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in fasted state will receive cilofexor 10 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 10 mg or placebo once daily from Day 7 to Day 20.
Drug: Cilofexor · Drug: Placebo
Participants in fasted state will receive cilofexor 30 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 30 mg or placebo once daily from Day 7 to Day 20.
Drug: Cilofexor · Drug: Placebo
Participants in fasted state will receive cilofexor 100 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 100 mg or placebo once daily from Day 7 to Day 20.
Drug: Cilofexor · Drug: Placebo
Participants in fasted state will receive cilofexor 300 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 300 mg or placebo once daily from Day 7 to Day 20.
Drug: Cilofexor · Drug: Placebo
Participants in fed state will receive cilofexor 100 mg or placebo once with food on Day 1 followed by a 5-day washout period then receive cilofexor 100 mg or placebo tablet, orally, once daily with food from Day 7 to Day 20.
Drug: Cilofexor · Drug: Placebo
Participants in fed state will receive cilofexor 50 mg or placebo twice with food on Day 1 followed by a 5-day washout period then receive cilofexor 50 mg or placebo twice daily from Day 7 to Day 20.
Drug: Cilofexor · Drug: Placebo
Participants in fed state will receive cilofexor 15 mg or placebo twice with food on Day 1 followed by a 5-day washout period then receive cilofexor 15 mg or placebo twice daily from Day 7 to Day 20.
Drug: Cilofexor · Drug: Placebo
Participants in fed state will receive cilofexor 10 mg or placebo once with food on Day 1 followed by a 5-day washout period then receive cilofexor 10 mg or placebo once daily from Day 7 to Day 20.
Drug: Cilofexor · Drug: Placebo
Participants will receive cilofexor up to 300 mg or placebo once daily in the evening on empty stomach.
Drug: Cilofexor · Drug: Placebo
Participants will receive cilofexor up to 300 mg or placebo once daily in the evening on empty stomach.
Drug: Cilofexor · Drug: Placebo
Tablets administered orally
Also known as: GS-9674
Tablets administered orally
Single-Dose Pharmacokinetic (PK) Parameter: AUClast of Cilofexor
AUClast is defined as the concentration of drug from time zero to the last quantifiable concentration.
Time frame: Day 1: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose
Single-Dose PK Parameter: AUCinf of Cilofexor
AUCinf is defined as the concentration of drug extrapolated to infinite time (area under the plasma concentration versus time curve extrapolated to infinite time).
Time frame: Day 1: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose
Single-Dose PK Parameter: Cmax of Cilofexor
Cmax is defined as the maximum observed concentration of drug in plasma.
Time frame: Day 1: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose
Multiple-Dose PK Parameter: AUCtau of Cilofexor
AUCtau is the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval).
Time frame: Day 20: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose
Multiple-Dose PK Parameter: Cmax of Cilofexor
Cmax is defined as the maximum observed concentration of drug in plasma.
Time frame: Day 20: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose
Multiple-Dose PK Parameter: Ctau of Cilofexor
Ctau is defined as the observed drug concentration at the end of the dosing interval.
Time frame: Day 20: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose
Percentage of Participants With at Least One Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant administered a medicinal product, which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: First dose date up to last dose date (Maximum: 20 days) plus 30 days
Percentage of Participants With Clinically Significant 12-Lead Electrocardiogram (ECG) Abnormalities
Investigator determined the ECG findings were clinically significant.
Time frame: First dose date up to last dose date (Maximum: 20 days) plus 30 days
Percentage of Participants With Clinical Laboratory Abnormalities
Treatment-emergent laboratory (Hematology, Chemistry, and Urinalysis) abnormalities were defined as values that increase at least one toxicity grade from baseline. Laboratory Abnormalities are graded by the investigator as Grade 1, 2, 3, or 4 according to the modified Gilead Sciences, Inc (GSI) Grading Scale. The most severe graded abnormality from all tests was counted for each participant. Data is only reported for those Grades reported in 1 or more participants.
Time frame: First dose date up to last dose date (Maximum: 20 days) plus 30 days
Pharmacodynamic (PD) Parameter: Fibroblast Growth Factor 19 (FGF19) AUC2-12 Ratio
AUC2-12 is defined as the AUC from time 2 to 12 hours. The ratios calculated were normalized to Day -1. Participants received a single placebo tablet at Day -1 for Baseline. The ratio reported for Day 1 is the AUC2-12 Day 1 /AUC2-12 Day-1. The ratio reported for Day 20 is the AUC2-12 Day 20 /AUC2-12 Day-1.
Time frame: Day -1: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, and 16 hours post-dose; Days 1, and 20: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose
PD Parameter: FGF19 Cmax Ratio
Cmax is defined as the maximum observed concentration of FGF19 in plasma. The ratios calculated were normalized to Day -1. Participants received a single placebo tablet at Day -1 for Baseline. The ratio reported for Day 1 is the Cmax Day 1 /Cmax Day-1. The ratio reported for Day 20 is the Cmax Day 20 /Cmax Day-1.
Time frame: Day -1: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, and 16 hours post-dose; Days 1, and 20: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose
PD Parameter: 7alpha-hydroxy-4-cholesten-3-one (C4) AUC2-12 Ratio
AUC2-12 is defined as the AUC from time 2 to 12 hours. The ratios calculated were normalized to Day -1. Participants received a single placebo tablet at Day -1 for Baseline. The ratio reported for Day 1 is the AUC2-12 Day 1 /AUC2-12 Day-1. The ratio reported for Day 20 is the AUC2-12 Day 20 /AUC2-12 Day-1.
Time frame: Day -1: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, and 16 hours post-dose; Days 1, and 20: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose
PD Parameter: C4 Cmin Ratio
Cmin is defined as the minimum observed concentration of C4 in plasma. The ratios calculated were normalized to Day -1. Participants received a single placebo tablet at Day -1 for Baseline. The ratio reported for Day 1 is the Cmin Day 1 /Cmin Day-1. The ratio reported for Day 20 is the Cmin Day 20 /Cmin Day-1.
Time frame: Day -1: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, and 16 hours post-dose; Days 1, and 20: -0.5, 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours post-dose
Participants were enrolled at one study site in the United States. The first participant was screened on 20 January 2016. The last study visit occurred on 14 July 2016.
| Milestone | Cohort 1: Cilofexor 10 mg | Cohort 2: Cilofexor 30 mg | Cohort 3: Cilofexor 100 mg | Cohort 4: Cilofexor 300 mg | Cohort 5: Cilofexor 100 mg | Cohort 6: Cilofexor 50 mg | Cohort 7: Cilofexor 15 mg | Cohort 8: Cilofexor 10 mg | All Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Started | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 24 |
| Completed | 12 | 12 | 12 | 12 | 12 | 11 | 11 | 11 | 24 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrew consent | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
AUClast is defined as the concentration of drug from time zero to the last quantifiable concentration.
| hours*nanogram/millilitre (h*ng/mL) | Cohort 1: Cilofexor 10 mg | Cohort 2: Cilofexor 30 mg | Cohort 3: Cilofexor 100 mg | Cohort 4: Cilofexor 300 mg | Cohort 5: Cilofexor 100 mg | Cohort 6: Cilofexor 50 mg | Cohort 7: Cilofexor 15 mg | Cohort 8: Cilofexor 10 mg |
|---|---|---|---|---|---|---|---|---|
| Single-Dose Pharmacokinetic (PK) Parameter: AUClast of Cilofexor | 1236.0 ± 384.65 | 2450.6 ± 921.70 | 7712.1 ± 7270.76 | 12458.8 ± 4223.12 | 4979.5 ± 2039.07 | 3091.4 ± 752.66 | 1301.9 ± 388.51 | 905.9 ± 210.24 |
AUCinf is defined as the concentration of drug extrapolated to infinite time (area under the plasma concentration versus time curve extrapolated to infinite time).
| h*ng/mL | Cohort 1: Cilofexor 10 mg | Cohort 2: Cilofexor 30 mg | Cohort 3: Cilofexor 100 mg | Cohort 4: Cilofexor 300 mg | Cohort 5: Cilofexor 100 mg | Cohort 6: Cilofexor 50 mg | Cohort 7: Cilofexor 15 mg | Cohort 8: Cilofexor 10 mg |
|---|---|---|---|---|---|---|---|---|
| Single-Dose PK Parameter: AUCinf of Cilofexor | 1255.9 ± 382.37 | 2473.4 ± 920.85 | 7743.7 ± 7273.50 | 12495.7 ± 4230.00 | 5016.7 ± 2022.94 | 3559.2 ± 1092.73 | 1409.3 ± 428.33 | 924.0 ± 216.60 |
Cmax is defined as the maximum observed concentration of drug in plasma.
| ng/mL | Cohort 1: Cilofexor 10 mg | Cohort 2: Cilofexor 30 mg | Cohort 3: Cilofexor 100 mg | Cohort 4: Cilofexor 300 mg | Cohort 5: Cilofexor 100 mg | Cohort 6: Cilofexor 50 mg | Cohort 7: Cilofexor 15 mg | Cohort 8: Cilofexor 10 mg |
|---|---|---|---|---|---|---|---|---|
| Single-Dose PK Parameter: Cmax of Cilofexor | 304.2 ± 126.66 | 580.2 ± 283.79 | 2592.3 ± 3059.31 | 3055.5 ± 2022.27 | 927.6 ± 540.94 | 665.9 ± 152.30 | 340.2 ± 124.44 | 209.8 ± 63.24 |
AUCtau is the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval).
| h*ng/mL | Cohort 1: Cilofexor 10 mg | Cohort 2: Cilofexor 30 mg | Cohort 3: Cilofexor 100 mg | Cohort 4: Cilofexor 300 mg | Cohort 5: Cilofexor 100 mg | Cohort 6: Cilofexor 50 mg | Cohort 7: Cilofexor 15 mg | Cohort 8: Cilofexor 10 mg |
|---|---|---|---|---|---|---|---|---|
| Multiple-Dose PK Parameter: AUCtau of Cilofexor | 1284.9 ± 460.35 | 2891.0 ± 680.10 | 6719.4 ± 3980.90 | 8486.0 ± 4139.86 | 4182.7 ± 1956.03 | 3698.3 ± 837.91 | 1293.5 ± 250.95 | 848.2 ± 213.82 |
Cmax is defined as the maximum observed concentration of drug in plasma.
| ng/mL | Cohort 1: Cilofexor 10 mg | Cohort 2: Cilofexor 30 mg | Cohort 3: Cilofexor 100 mg | Cohort 4: Cilofexor 300 mg | Cohort 5: Cilofexor 100 mg | Cohort 6: Cilofexor 50 mg | Cohort 7: Cilofexor 15 mg | Cohort 8: Cilofexor 10 mg |
|---|---|---|---|---|---|---|---|---|
| Multiple-Dose PK Parameter: Cmax of Cilofexor | 322.2 ± 136.70 | 717.5 ± 235.50 | 2231.2 ± 1693.78 | 2327.9 ± 1897.48 | 818.7 ± 437.28 | 697.8 ± 145.60 | 290.4 ± 78.71 | 187.0 ± 57.10 |
Ctau is defined as the observed drug concentration at the end of the dosing interval.
| ng/mL | Cohort 1: Cilofexor 10 mg | Cohort 2: Cilofexor 30 mg | Cohort 3: Cilofexor 100 mg | Cohort 4: Cilofexor 300 mg | Cohort 5: Cilofexor 100 mg | Cohort 6: Cilofexor 50 mg | Cohort 7: Cilofexor 15 mg | Cohort 8: Cilofexor 10 mg |
|---|---|---|---|---|---|---|---|---|
| Multiple-Dose PK Parameter: Ctau of Cilofexor | 2.7 ± 1.53 | 7.9 ± 3.97 | 36.3 ± 15.44 | 70.1 ± 39.46 | 22.6 ± 8.44 | 107.6 ± 84.58 | 28.4 ± 14.13 | 3.0 ± 1.54 |
An AE is any untoward medical occurrence in a clinical study participant administered a medicinal product, which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
| percentage of participants | Cohort 1: Cilofexor 10 mg | Cohort 2: Cilofexor 30 mg | Cohort 3: Cilofexor 100 mg | Cohort 4: Cilofexor 300 mg | Cohort 5: Cilofexor 100 mg | Cohort 6: Cilofexor 50 mg | Cohort 7: Cilofexor 15 mg | Cohort 8: Cilofexor 10 mg | All Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With at Least One Adverse Event (AE) | 33.3 | 25.0 | 33.3 | 25.0 | 41.7 | 27.3 | 75.0 | 18.2 | 29.2 |
Investigator determined the ECG findings were clinically significant.
| percentage of participants | Cohort 1: Cilofexor 10 mg | Cohort 2: Cilofexor 30 mg | Cohort 3: Cilofexor 100 mg | Cohort 4: Cilofexor 300 mg | Cohort 5: Cilofexor 100 mg | Cohort 6: Cilofexor 50 mg | Cohort 7: Cilofexor 15 mg | Cohort 8: Cilofexor 10 mg | All Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Clinically Significant 12-Lead Electrocardiogram (ECG) Abnormalities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Treatment-emergent laboratory (Hematology, Chemistry, and Urinalysis) abnormalities were defined as values that increase at least one toxicity grade from baseline. Laboratory Abnormalities are graded by the investigator as Grade 1, 2, 3, or 4 according to the modified Gilead Sciences, Inc (GSI) Grading Scale. The most severe graded abnormality from all tests was counted for each participant. Data is only reported for those Grades reported in 1 or more participants.
| percentage of participants | Cohort 1: Cilofexor 10 mg | Cohort 2: Cilofexor 30 mg | Cohort 3: Cilofexor 100 mg | Cohort 4: Cilofexor 300 mg | Cohort 5: Cilofexor 100 mg | Cohort 6: Cilofexor 50 mg | Cohort 7: Cilofexor 15 mg | Cohort 8: Cilofexor 10 mg | All Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Activated Partial Thromboplastin Time: Grade 1 | 0.0 | 8.3 | 16.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Hemoglobin-Hypo: Grade 1 | 16.7 | 25.0 | 16.7 | 8.3 | 16.7 | 18.2 | 25.0 | 27.3 | 29.2 |
| Hemoglobin-Hypo: Grade 2 | 0.0 | 0.0 | 8.3 | 8.3 | 8.3 | 0.0 | 16.7 | 9.1 | 8.3 |
| Hemoglobin-Hypo: Grade 3 | 0.0 | 0.0 | 0.0 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| International Normalized Ratio: Grade 2 | 0.0 | 0.0 | 0.0 | 0.0 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 |
| Lymphocytes: Grade 1 | 0.0 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Platelets: Grade 2 | 0.0 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Alanine Aminotransferase: Grade 1 | 0.0 | 0.0 | 0.0 | 8.3 | 0.0 | 0.0 | 0.0 | 9.1 | 4.2 |
| Alanine Aminotransferase: Grade 2 | 0.0 | 16.7 | 0.0 | 0.0 | 8.3 | 9.1 | 0.0 | 0.0 | 4.2 |
| Alanine Aminotransferase: Grade 3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 8.3 | 0.0 | 0.0 |
| Aspartate Aminotransferase: Grade 1 | 0.0 | 0.0 | 0.0 | 0.0 | 8.3 | 9.1 | 0.0 | 0.0 | 4.2 |
| Aspartate Aminotransferase: Grade 2 | 0.0 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 8.3 | 0.0 | 0.0 |
| Aspartate Aminotransferase: Grade 3 | 0.0 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Aspartate Aminotransferase: Grade 4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.2 |
| Albumin Corrected Calcium-Hyper: Grade 1 | 0.0 | 0.0 | 0.0 | 8.3 | 8.3 | 9.1 | 8.3 | 0.0 | 4.2 |
| Gamma-Glutamyltransferase: Grade 1 | 0.0 | 0.0 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.2 |
| Gamma-Glutamyltransferase: Grade 2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 8.3 | 0.0 | 0.0 |
| Low-Density Lipoprotein: Grade 1 | 8.3 | 0.0 | 8.3 | 8.3 | 25.0 | 27.3 | 25.0 | 18.2 | 12.5 |
| Low-Density Lipoprotein: Grade 2 | 8.3 | 8.3 | 8.3 | 8.3 | 16.7 | 0.0 | 8.3 | 0.0 | 4.2 |
| Phosphate-Hypo: Grade 1 | 0.0 | 8.3 | 0.0 | 8.3 | 8.3 | 0.0 | 8.3 | 9.1 | 4.2 |
| Phosphate-Hypo: Grade 2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.2 |
| Serum Amylase: Grade 1 | 0.0 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Serum Amylase: Grade 2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 9.1 | 4.2 |
| Serum Glucose,Fasting-Hyper: Grade 1 | 0.0 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Serum Glucose,Fasting-Hyper:Grade 2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 9.1 | 0.0 |
| Serum Glucose,Non-Fasting-Hyper:Grade 1 | 0.0 | 0.0 | 0.0 | 0.0 | 58.3 | 0.0 | 18.2 | 0.0 | 4.2 |
| Serum Glucose,Non-Fasting-Hyper:Grade 2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 9.1 | 0.0 |
| Serum Glucose,Non-Fasting-Hypo:Grade 1 | 0.0 | 0.0 | 0.0 | 0.0 | 8.3 | 0.0 | 0.0 | 0.0 | 4.2 |
| Serum Potassium-Hypo:Grade 1 | 0.0 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 27.3 | 0.0 |
| Serum Sodium-Hyper:Grade 1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 9.1 | 0.0 |
| Serum Sodium-Hypo:Grade 1 | 8.3 | 25.0 | 8.3 | 0.0 | 0.0 | 18.2 | 50.0 | 9.1 | 4.2 |
| Total Bilirubin-Hyper:Grade 1 | 0.0 | 0.0 | 0.0 | 8.3 | 0.0 | 0.0 | 0.0 | 9.1 | 4.2 |
| Total Cholesterol-Hyper:Grade 1 | 16.7 | 0.0 | 16.7 | 16.7 | 25.0 | 36.4 | 25.0 | 9.1 | 12.5 |
| Total Cholesterol-Hyper:Grade 2 | 8.3 | 0.0 | 8.3 | 0.0 | 16.7 | 0.0 | 8.3 | 9.1 | 4.2 |
| Uric Acid-Hyper:Grade 1 | 0.0 | 0.0 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Uric Acid-Hypo:Grade 1 | 8.3 | 16.7 | 0.0 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Occult Blood: Grade 1 | 0.0 | 0.0 | 8.3 | 0.0 | 8.3 | 0.0 | 0.0 | 9.1 | 8.3 |
| Occult Blood: Grade 2 | 16.7 | 8.3 | 0.0 | 8.3 | 0.0 | 0.0 | 0.0 | 9.1 | 12.5 |
| Occult Blood: Grade 3 | 25.0 | 8.3 | 8.3 | 16.7 | 8.3 | 18.2 | 16.7 | 18.2 | 8.3 |
| Urine Glucose: Grade 1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 9.1 | 0.0 |
| Urine Protein: Grade 1 | 0.0 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.2 |
AUC2-12 is defined as the AUC from time 2 to 12 hours. The ratios calculated were normalized to Day -1. Participants received a single placebo tablet at Day -1 for Baseline. The ratio reported for Day 1 is the AUC2-12 Day 1 /AUC2-12 Day-1. The ratio reported for Day 20 is the AUC2-12 Day 20 /AUC2-12 Day-1.
| ratio | Cohort 1: Cilofexor 10 mg | Cohort 2: Cilofexor 30 mg | Cohort 3: Cilofexor 100 mg | Cohort 4: Cilofexor 300 mg | All Fasted Placebo | Cohort 5: Cilofexor 100 mg | Cohort 6: Cilofexor 50 mg | Cohort 7: Cilofexor 15 mg | Cohort 8: Cilofexor 10 mg | All Fed Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1/Day -1 | 2.040 (1.571 to 2.650) | 1.958 (1.478 to 2.594) | 2.037 (1.699 to 2.442) | 2.314 (1.958 to 2.735) | 0.981 (0.777 to 1.240) | 2.406 (2.196 to 2.637) | 2.629 (2.369 to 2.917) | 1.743 (1.463 to 2.076) | 1.372 (1.132 to 1.663) | 0.916 (0.799 to 1.050) |
| Day 20/Day -1 | 2.270 (1.500 to 3.435) | 2.261 (1.782 to 2.868) | 2.054 (1.727 to 2.442) | 2.179 (1.632 to 2.911) | 1.249 (0.929 to 1.681) | 1.795 (1.544 to 2.086) | 2.119 (1.728 to 2.598) | 1.650 (1.301 to 2.093) | 1.509 (1.325 to 1.719) | 0.963 (0.762 to 1.216) |
Cmax is defined as the maximum observed concentration of FGF19 in plasma. The ratios calculated were normalized to Day -1. Participants received a single placebo tablet at Day -1 for Baseline. The ratio reported for Day 1 is the Cmax Day 1 /Cmax Day-1. The ratio reported for Day 20 is the Cmax Day 20 /Cmax Day-1.
| ratio | Cohort 1: Cilofexor 10 mg | Cohort 2: Cilofexor 30 mg | Cohort 3: Cilofexor 100 mg | Cohort 4: Cilofexor 300 mg | All Fasted Placebo | Cohort 5: Cilofexor 100 mg | Cohort 6: Cilofexor 50 mg | Cohort 7: Cilofexor 15 mg | Cohort 8: Cilofexor 10 mg | All Fed Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1/Day -1 | 2.217 (1.667 to 2.949) | 2.084 (1.468 to 2.957) | 2.259 (1.742 to 2.930) | 2.679 (2.113 to 3.398) | 0.982 (0.759 to 1.272) | 2.793 (2.264 to 3.446) | 2.973 (2.578 to 3.428) | 1.961 (1.588 to 2.422) | 1.689 (1.354 to 2.106) | 0.929 (0.810 to 1.065) |
| Day 20/Day -1 | 2.157 (1.345 to 3.460) | 2.393 (1.770 to 3.235) | 2.325 (1.804 to 2.996) | 3.084 (2.194 to 4.334) | 1.210 (0.910 to 1.608) | 2.241 (1.850 to 2.713) | 2.455 (1.964 to 3.069) | 1.768 (1.270 to 2.462) | 1.878 (1.527 to 2.310) | 0.874 (0.680 to 1.123) |
AUC2-12 is defined as the AUC from time 2 to 12 hours. The ratios calculated were normalized to Day -1. Participants received a single placebo tablet at Day -1 for Baseline. The ratio reported for Day 1 is the AUC2-12 Day 1 /AUC2-12 Day-1. The ratio reported for Day 20 is the AUC2-12 Day 20 /AUC2-12 Day-1.
| ratio | Cohort 1: Cilofexor 10 mg | Cohort 2: Cilofexor 30 mg | Cohort 3: Cilofexor 100 mg | Cohort 4: Cilofexor 300 mg | All Fasted Placebo | Cohort 5: Cilofexor 100 mg | Cohort 6: Cilofexor 50 mg | Cohort 7: Cilofexor 15 mg | Cohort 8: Cilofexor 10 mg | All Fed Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1/Day -1 | 0.681 (0.431 to 1.077) | 0.640 (0.516 to 0.794) | 0.427 (0.340 to 0.537) | 0.347 (0.278 to 0.433) | 1.147 (0.921 to 1.429) | 0.837 (0.629 to 1.114) | 0.653 (0.581 to 0.735) | 0.863 (0.747 to 0.997) | 1.108 (0.828 to 1.483) | 1.057 (0.893 to 1.252) |
| Day 20/Day -1 | 0.661 (0.456 to 0.959) | 0.382 (0.277 to 0.525) | 0.495 (0.348 to 0.704) | 0.325 (0.223 to 0.474) | 1.213 (0.828 to 1.777) | 0.621 (0.414 to 0.933) | 0.173 (0.109 to 0.275) | 0.624 (0.472 to 0.825) | 0.974 (0.677 to 1.402) | 0.843 (0.681 to 1.043) |
Cmin is defined as the minimum observed concentration of C4 in plasma. The ratios calculated were normalized to Day -1. Participants received a single placebo tablet at Day -1 for Baseline. The ratio reported for Day 1 is the Cmin Day 1 /Cmin Day-1. The ratio reported for Day 20 is the Cmin Day 20 /Cmin Day-1.
| ratio | Cohort 1: Cilofexor 10 mg | Cohort 2: Cilofexor 30 mg | Cohort 3: Cilofexor 100 mg | Cohort 4: Cilofexor 300 mg | All Fasted Placebo | Cohort 5: Cilofexor 100 mg | Cohort 6: Cilofexor 50 mg | Cohort 7: Cilofexor 15 mg | Cohort 8: Cilofexor 10 mg | All Fed Placebo |
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1/Day -1 | 0.715 (0.531 to 0.964) | 0.759 (0.597 to 0.964) | 0.663 (0.542 to 0.810) | 0.467 (0.370 to 0.589) | 1.201 (0.941 to 1.532) | 0.613 (0.497 to 0.756) | 0.348 (0.260 to 0.467) | 0.737 (0.590 to 0.921) | 0.961 (0.787 to 1.173) | 1.162 (0.981 to 1.377) |
| Day 20/Day -1 | 0.822 (0.580 to 1.163) | 0.456 (0.303 to 0.687) | 0.624 (0.458 to 0.850) | 0.432 (0.277 to 0.675) | 1.262 (0.901 to 1.767) | 0.440 (0.264 to 0.733) | 0.116 (0.071 to 0.192) | 0.508 (0.334 to 0.773) | 0.862 (0.666 to 1.115) | 0.983 (0.718 to 1.346) |
Collected over First dose date up to last dose date (Maximum: 20 days) plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Cilofexor 10 mg | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| Cohort 2: Cilofexor 30 mg | 0/12 (0%) | 0/12 (0%) | 3/12 (25%) |
| Cohort 3: Cilofexor 100 mg | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| Cohort 4: Cilofexor 300 mg | 0/12 (0%) | 0/12 (0%) | 3/12 (25%) |
| Cohort 5: Cilofexor 100 mg | 0/12 (0%) | 0/12 (0%) | 5/12 (41.7%) |
| Cohort 6: Cilofexor 50 mg | 0/11 (0%) | 0/11 (0%) | 3/11 (27.3%) |
| Cohort 7: Cilofexor 15 mg | 0/12 (0%) | 0/12 (0%) | 9/12 (75%) |
| Cohort 8: Cilofexor 10 mg | 0/11 (0%) | 0/11 (0%) | 2/11 (18.2%) |
| All Placebo | 0/24 (0%) | 0/24 (0%) | 6/24 (25%) |
| Event | Cohort 1: Cilofexor 10 mg | Cohort 2: Cilofexor 30 mg | Cohort 3: Cilofexor 100 mg | Cohort 4: Cilofexor 300 mg | Cohort 5: Cilofexor 100 mg | Cohort 6: Cilofexor 50 mg | Cohort 7: Cilofexor 15 mg | Cohort 8: Cilofexor 10 mg | All Placebo |
|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/12 | 0/12 | 0/12 | 1/12 | 2/12 | 1/11 | 5/12 | 0/11 | 3/24 |
| AnaemiaBlood and lymphatic system disorders | 0/12 | 0/12 | 0/12 | 0/12 | 2/12 | 0/11 | 0/12 | 0/11 | 0/24 |
| DiarrhoeaGastrointestinal disorders | 0/12 | 0/12 | 0/12 | 0/12 | 2/12 | 0/11 | 1/12 | 0/11 | 0/24 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/11 | 0/12 | 1/11 | 0/24 |
| Back painMusculoskeletal and connective tissue disorders | 1/12 | 1/12 | 1/12 | 0/12 | 1/12 | 1/11 | 0/12 | 0/11 | 0/24 |
| SciaticaNervous system disorders | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/11 | 0/12 | 1/11 | 0/24 |
| EcchymosisSkin and subcutaneous tissue disorders | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 1/11 | 0/12 | 0/11 | 0/24 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/12 | 0/12 | 1/12 | 1/12 | 0/12 | 0/11 | 1/12 | 0/11 | 1/24 |
| Ocular discomfortEye disorders | 1/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/11 | 0/12 | 0/11 | 0/24 |
| Abdominal painGastrointestinal disorders | 0/12 | 0/12 | 0/12 | 0/12 | 1/12 | 0/11 | 1/12 | 0/11 | 0/24 |
The Safety Analysis Set included all randomized participants who took at least 1 dose of study drug. Participants were grouped according to the treatment they actually received.
| Age, Continuous(years) | Cohort 1: Cilofexor 10 mg | Cohort 2: Cilofexor 30 mg | Cohort 3: Cilofexor 100 mg | Cohort 4: Cilofexor 300 mg | Cohort 5: Cilofexor 100 mg | Cohort 6: Cilofexor 50 mg | Cohort 7: Cilofexor 15 mg | Cohort 8: Cilofexor 10 mg | All Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 34 ± 6.5 | 35 ± 8.9 | 37 ± 6.1 | 32 ± 8.7 | 40 ± 4.6 | 33 ± 7.4 | 35 ± 6.0 | 35 ± 7.1 | 36 ± 6.7 | 35 ± 7.1 |
| Sex: Female, Male(Participants) | Cohort 1: Cilofexor 10 mg | Cohort 2: Cilofexor 30 mg | Cohort 3: Cilofexor 100 mg | Cohort 4: Cilofexor 300 mg | Cohort 5: Cilofexor 100 mg | Cohort 6: Cilofexor 50 mg | Cohort 7: Cilofexor 15 mg | Cohort 8: Cilofexor 10 mg | All Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 6 | 4 | 5 | 4 | 5 | 6 | 7 | 8 | 14 | 59 |
| Male | 6 | 8 | 7 | 8 | 7 | 5 | 5 | 3 | 10 | 59 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: Cilofexor 10 mg | Cohort 2: Cilofexor 30 mg | Cohort 3: Cilofexor 100 mg | Cohort 4: Cilofexor 300 mg | Cohort 5: Cilofexor 100 mg | Cohort 6: Cilofexor 50 mg | Cohort 7: Cilofexor 15 mg | Cohort 8: Cilofexor 10 mg | All Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 11 | 12 | 11 | 12 | 12 | 11 | 12 | 11 | 24 | 116 |
| Not Hispanic or Latino | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: Cilofexor 10 mg | Cohort 2: Cilofexor 30 mg | Cohort 3: Cilofexor 100 mg | Cohort 4: Cilofexor 300 mg | Cohort 5: Cilofexor 100 mg | Cohort 6: Cilofexor 50 mg | Cohort 7: Cilofexor 15 mg | Cohort 8: Cilofexor 10 mg | All Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Race — Black | 1 | 1 | 2 | 3 | 2 | 2 | 1 | 2 | 2 | 16 |
| Race — White | 11 | 11 | 10 | 9 | 10 | 9 | 11 | 9 | 22 | 102 |
| Region of Enrollment(participants) | Cohort 1: Cilofexor 10 mg | Cohort 2: Cilofexor 30 mg | Cohort 3: Cilofexor 100 mg | Cohort 4: Cilofexor 300 mg | Cohort 5: Cilofexor 100 mg | Cohort 6: Cilofexor 50 mg | Cohort 7: Cilofexor 15 mg | Cohort 8: Cilofexor 10 mg | All Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | 12 | 12 | 12 | 12 | 12 | 11 | 12 | 11 | 24 | 118 |
Ran from Jan 2016 to primary completion in Jul 2016, 5 months.
Results were first posted in Oct 2020, 4 years 2 months after primary completion.
Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 5 months is below that.
Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cilofexor
Non-alcoholic Fatty Liver Disease →